Open AccessIncreasing Age at HIV Seroconversion From 18 to 40 Years Is Associated With Favorable Virologic and Immunologic Responses to HAART
Author(s) -
Amy C. Weintrob,
Ann Fieberg,
Brian K. Agan,
Anuradha Ganesan,
Nancy F. Crum-Cianflone,
Vincent C. Marconi,
Mollie Roediger,
Susan Fraser,
Scott A. Wegner,
Glenn Wortmann
Publication year - 2008
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31817bec05
Subject(s) - seroconversion , medicine , hazard ratio , confidence interval , viral load , immunology , multicenter aids cohort study , proportional hazards model , cohort , young adult , viral disease , human immunodeficiency virus (hiv) , antiretroviral therapy
Studies evaluating the effect of age on response to highly active antiretroviral therapy (HAART) have been limited by their inability to control for duration of human immunodeficiency virus (HIV) infection. We examined the effect of age at HIV seroconversion on response to HAART.